Various adverse effects particularly cutaneous manifestations associated with different
COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with
skin manifestations following
COVID-19 vaccines injection from September to December 2021. All patients with
skin manifestation within 30 days or less following
COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm
vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca
vaccine. Six (24%) patients developed new-onset
lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed
psoriasis and 1 (4%) case showed
psoriasis exacerbation. One (4%) patient developed new-onset
pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested
pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows:
toxic epidermal necrolysis (TEN) (n = 1, 4%),
bullous pemphigoid (BP) (n = 2, 8%),
alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%),
herpes zoster (n = 1, 4%), cutaneous small vessel
vasculitis (n = 1, 4%),
erythema multiform (EM) and
urticaria (n = 3, 12%), and
morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with
COVID-19 vaccines.